Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

Inclusion Criteria

• •Patients or their health care proxies must be able to provide consent to participate in this trial.
• •Patients must have one of the following diagnoses which has not responded or recurred following at least one prior chemotherapy regimen or radiation therapy:
• •* anaplastic astrocytoma, glioblastoma multiforme or oligodendroglioma
• •* primary CNS lymphoma
• •* malignant disease metastatic to the CNS
• •Patients must be candidates for high dose chemotherapy and autologous stem cell transplant according to the following criteria:
• •* Patients must be between the ages of 18 and 70 years (inclusive)
• •* Patients must have a left ventricular ejection fraction greater than or equal to 45% by MUGA or echocardiogram
• •* Patients must have adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% of predicted
• •* Patients must have serum direct bilirubin less than or equal to 2.0 mg/dl and transaminases less than or equal to 3x institutional upper limit of normal
• •* Patients must have serum creatinine less than or equal to 2 mg/dl with creatinine clearance greater than or equal to 60 ml/min (either calculated or measured)
• •* Patients must have an ECOG performance status between 0 and 2
• •Patients must be at least 4 weeks from last cytoreductive chemotherapy.
• •Expected survival of at least 3 months